Recent 8-K filings for RCKT

• May 7, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  Rocket Pharma Q1 net loss $47.6M; KRESLADI gets FDA accelerated approval; PRV sold for $180M

  Net loss of $47.6M ($0.42/sh) narrowed from $61.3M ($0.56/sh) YoY.

• April 28, 2026, 7:59 PM ET other material materiality 0.80 positive item 1.01item 7.01item 9.01 ◈ Material Agreements

  Rocket Pharmaceuticals sells Rare Pediatric Disease PRV for $180M, extending cash runway to Q2 2028

  Enters definitive agreement to sell PRV for $180M in cash; closing subject to HSR antitrust waiting period.

• March 27, 2026, 7:59 PM ET regulatory materiality 0.90 positive item 7.01item 9.01

  FDA approves Rocket's gene therapy KRESLADI for severe LAD-I; Rare Pediatric PRV granted

  KRESLADI (marnetegragene autotemcel) approved for pediatric severe LAD-I with no HLA-matched sibling donor.

• February 26, 2026, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Rocket Pharma FY2025 net loss $223.1M; cash $188.9M; KRESLADI PDUFA March 28, 2026

  Net loss $223.1M ($2.01/shr) vs $258.7M ($2.73/shr) in FY2024; R&D spend down 17% to $142.0M.

• November 6, 2025, 6:59 PM ET earnings materiality 0.65 positive item 2.02item 9.01

  Rocket Pharma Q3 net loss $50.3M; KRESLADI PDUFA March 2026; Danon trial to resume 1H 2026

  Q3 net loss $50.3M ($0.45/share), down from $66.7M ($0.71) YoY; R&D expenses $34.1M vs $42.3M.

• October 14, 2025, 7:59 PM ET regulatory materiality 0.80 positive item 8.01item 9.01

  Rocket Pharma: FDA accepts BLA resubmission for KRESLADI gene therapy; PDUFA March 28, 2026

  FDA accepted BLA resubmission for KRESLADI (marne-cel) for severe LAD-I; PDUFA target date March 28, 2026.

• October 3, 2025, 7:59 PM ET regulatory materiality 0.75 negative item 8.01

  Rocket Pharma withdraws BLA for RP-L102 (Fanconi anemia gene therapy) as part of corporate prioritization

  Voluntarily withdrew BLA for RP-L102 (mozafancogene autotemcel) from FDA on October 3, 2025.

• September 17, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 1.01item 9.01

  Rocket Pharma finalizes Dr. Patel separation; consulting through Dec 2026 with $582K retainer

  Dr. Kinnari Patel receives $482,040 lump-sum severance (10 months salary) and $30,045 healthcare allowance.

• August 20, 2025, 7:59 PM ET regulatory materiality 0.85 positive item 8.01item 9.01

  Rocket Pharmaceuticals: FDA lifts clinical hold on Phase 2 trial of RP-A501 for Danon disease

  FDA lifted clinical hold in under 3 months; trial resumes with recalibrated dose 3.8x10^13 GC/kg for 3 patients with 4-week intervals.

• August 7, 2025, 7:59 PM ET leadership materiality 0.80 negative item 2.02item 5.02item 9.01

  Rocket Pharmaceuticals: President Patel to depart, 30% workforce cut, Q2 net loss $68.9M

  Dr. Kinnari Patel to leave as President and Head of R&D effective Dec 31, 2025; steps down Aug 8.

• July 24, 2025, 7:59 PM ET other material materiality 0.65 negative item 8.01item 9.01

  Rocket Pharma restructures, cuts headcount 30%, delays FA/PKD programs; cash runway to Q2 2027

  Headcount reduction of ~30% and 12-month cash burn reduction of ~25% as part of corporate reorganization.

• July 23, 2025, 7:59 PM ET other material materiality 0.70 negative item 2.05 ◈ Restructurings & Charges

  Rocket Pharmaceuticals cuts workforce 30%, extends cash runway into Q2 2027

  Reduction in workforce of ~30%; expected to cut 12-month operating expenses by ~25%.

• July 17, 2025, 7:59 PM ET regulatory materiality 0.70 positive item 8.01item 9.01

  FDA grants RMAT designation to Rocket Pharma's RP-A601 gene therapy for PKP2-ACM

  FDA granted RMAT designation for RP-A601 (AAV-based gene therapy) for PKP2-arrhythmogenic cardiomyopathy.

• May 27, 2025, 7:59 PM ET regulatory materiality 0.90 negative item 7.01item 9.01

  Rocket Pharma announces FDA clinical hold on Phase 2 Danon gene therapy trial after patient death

  Patient in Phase 2 trial of RP-A501 experienced SAE (capillary leak syndrome) and later died due to acute systemic infection.

• May 15, 2025, 7:59 PM ET other material materiality 0.60 positive item 7.01item 8.01item 9.01

  Rocket Pharma reports positive Phase 1 data for RP-A601 in PKP2-ACM

  RP-A601 well-tolerated; no dose-limiting toxicities in 3 patients with up to 12 months follow-up.

• May 8, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Rocket Pharma Q1 net loss $61.3M; cash $318.2M; pipeline on track

  Net loss of $61.3M ($0.56/share) vs $62.1M in Q1 2024; R&D expenses down to $35.9M.

• February 27, 2025, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Rocket Pharma FY2024 net loss $258.7M ($2.73/sh); cash $372.3M; RP-A501 Phase 2 ongoing

  Net loss $258.7M ($2.73/sh) for FY2024 vs $245.6M ($2.92/sh) in FY2023.

• December 12, 2024, 6:59 PM ET other material materiality 0.85 neutral item 1.01item 8.01item 9.01

  Rocket Pharmaceuticals raises ~$182.8M in public offering and private placement

  Public offering of 15.18M shares at $12.50/sh, including full exercise of underwriters' option; net proceeds ~$178.1M.

• November 18, 2024, 6:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Rocket Pharma reports positive long-term Phase 1 Danon Disease data; PKD program enrollment delayed to 2025

  All evaluable Danon disease patients showed cardiac LAMP2 protein expression at 12 months, sustained up to 60 months, and ≥10% LV mass index reduction sustained up to 54 months.

• November 7, 2024, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Rocket Pharma Q3 2024 net loss $198.4M; cash $235.7M; pipeline advances

  Net loss $198.4M ($2.11/share) for nine months ended Sept 30, 2024, vs $185.9M ($2.30/share) prior year.

• August 5, 2024, 7:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01

  Rocket Pharma H1 2024 net loss $131.7M; KRESLADI review ongoing, cash into 2026

  Net loss of $131.7M ($1.40/sh) for H1 2024 vs $124.0M ($1.55/sh) for H1 2023.

• June 28, 2024, 7:59 PM ET regulatory materiality 0.85 negative item 8.01item 9.01

  Rocket Pharma receives FDA Complete Response Letter for KRESLADI BLA; limited CMC info requested

  FDA issued Complete Response Letter for KRESLADI (marne-cel) BLA; requested limited additional CMC information.

• June 20, 2024, 7:59 PM ET other material materiality 0.60 neutral item 5.03item 5.07item 9.01

  Rocket Pharma increases authorized shares to 180M after shareholder approval

  Authorized common shares increased from 120M to 180M (50% increase); amendment effective June 20, 2024.

• May 6, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases

  Rocket Pharma Q1 net loss $62.1M; cash $330.3M; EMA accepted MAA for FA, PDUFA date June 30 for LAD-I

  Net loss of $62.1M ($0.66/sh) vs $58.3M ($0.73/sh) in Q1 2023; G&A rose to $22.1M on commercial prep.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.62 · Most common event leadership

9 positive 8 negative 19 neutral

source · RCKT on sec.gov